Viewing Study NCT00346957



Ignite Creation Date: 2024-05-05 @ 4:55 PM
Last Modification Date: 2024-10-26 @ 9:26 AM
Study NCT ID: NCT00346957
Status: COMPLETED
Last Update Posted: 2012-03-06
First Post: 2006-06-28

Brief Title: A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
Sponsor: Alcon Research
Organization: Alcon Research

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2012-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to determine the concentration of anecortave acetate 15 or 30 mg versus placebo that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None